Ordinary Shares, nominal value £0.003 per share
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 2.02, 9.01 · 8-K
Mereo BioPharma Group plc
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 11, 2026, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent corporate developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights →Company context
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in ADO2. āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Mereo BioPharma Group plcOct 28, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 19, 2026
- 10-Q filingAug 11, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 11, 2026
- Submission of Matters to a Vote of Security HoldersMay 14, 2026
Registered securities in this filing
MEREO BIOPHARMA GROUP PLC · 8-K · Filed 2026-08-11
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share
- Symbol
- MREO
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2026, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent corporate developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026 Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027 London, August 11, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights. The Company is also updating its previous cash runway guidance. As of June 30, 2026, cash and cash equivalents were approximately $30 million, which are expected to fund operations into late-2027. “The partnership with Sentynl Therapeutics which we announced earl…
Open exhibit ↗